Results
After the patients with incomplete data were excluded, 145 patients (100
men and 45 women) were evaluated. The mean age of the patients was 47.0
± 15.0 years, and the mean body mass index (BMI) was 26.93 ± 6.18
kg/m2. The stone localization was grouped as proximal
(n = 71), middle (n = 31), and distal ureter (n =
43) and the mean stone width and length was 9.2 ± 4.0 mm and 11.6 ± 5.9
mm, respectively. Demographic data and other characteristics of the
patients are summarized in Table 1.
The mean urinary symptoms scores were 30.87 ± 9.43 and 22.61 ± 6.78 at
first visit and before stent removal (after mirabegron therapy),
respectively (p < 0.0001). The mean body pain scores
were 21.82 ± 11.22 and 14.03 ± 7.52 (p < 0.0001); the
mean work performance scores were 10.50 ± 8.61 days and 7.02 ± 6.51 days
(p < 0.0001); the mean general health scores were 15.43
± 6.50 and 11.12 ± 3.70 (p < 0.0001); the mean sexual
matters scores were 3.88 ± 3.40 and 2.48 ± 2.03 (p <
0.0001); the mean additional problems scores were 9.31 ± 4.61 and 6.51 ±
2.83 (p < 0.0001); and the global quality of life (QoL)
scores were 5.18 ± 1.94 and 4.23 ± 1.71 at the first control visit and
after mirabegron monotherapy (p < 0.0001), respectively
(Table 2).